| |
AbCellera is leveraging its T-cell engager platform to generate molecules with potent tumor-cell killing and reduced cytokine release for multiple tumor targets, including peptide-MHCs. Explore more. 
|
|
Today’s Big NewsApr 30, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
| By Nick Paul Taylor Novartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand a peptide-drug conjugate collaboration. |
|
|
|
By Annalee Armstrong Newron Pharmaceuticals’ add-on schizophrenia treatment improved both positive and negative symptoms as well as severity in patients with the disorder during a phase 2/3 study. |
By Max Bayer Harmony Biosciences is spending $35 million upfront to buy Epygenix and its epilepsy meds. It's the neuroscience biotech's second deal in less than a month after it bought an orexin-2 inhibitor from Bioproject. |
By Gabrielle Masson NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression severity in a phase 2/3 trial, though the biotech is pressing forward to a registrational study with the belief that the candidate could eventually become a “paradigm-changing blockbuster drug.” |
By Annalee Armstrong The U.S. FDA is planning to hold an advisory committee meeting on…well, advisory committee meetings. |
By Annalee Armstrong Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received buntanetap, however digging a little deeper into the muddled readout suggests the trial was a failure. |
By Helen Floersh Finally, some bloody good news: Researchers have identified new enzymes that bring science closer to developing universal donor blood. In an article in Nature Microbiology, a team of researchers from the Technical University of Denmark and Lund University detailed how they discovered gut bacteria enzymes that remove not only A and B antigens from red blood cells but also other components that have historically hampered progress toward universal donor blood. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Heather Landi Walmart is shuttering all 51 health centers along with its virtual care services, the retail giant announced Tuesday morning. |
By Angus Liu Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter. But both meds had some bad news to report from late-stage clinical trials. |
By Conor Hale Philips has reached a $1.1 billion agreement to settle claims from about 58,000 people stemming from its yearslong recall of home CPAP ventilators and sleep apnea machines. |
By Paige Minemyer A new study aims to establish an ethical framework that can be used to ensure the patients who need these therapies can access them amid shortages. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report. |
|
|---|
|
|
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
